1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Theralink Technologies, Inc.

Theralink Technologies, Inc.

THER
Theralink Technologies, Inc.US flagOther OTC
0.00
USD
- -
- -
615,149.00Market Cap
Theralink Technologies, Inc.
THER
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
446.17
1,306.1
- -
0.04
- -
0.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-98.98
-1,754.33
-1,592.88
-528.32
-1,258.14
-7.24
-703.36
-15.08
-25.91
-119.37
20.74
-19
-0.06
- -
- -
-0.01
- -
Basic EPS, GAAP
-75.78
-2,905.3
-1,013.63
-1,066.26
-618.32
-6.68
-300.91
-13.14
-19.87
-13.65
-5.39
-2.37
-0.05
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-421.16
-2,168.39
-3,761.27
-4,282.63
-5,512.26
-2.14
-6,215.61
-17.11
-40.36
-137.57
-55.12
-53.73
-0.5
-0.01
-0.01
-0.02
-0.02
Book Value per Share
-85.91
255.31
-832.23
102.95
-1,581.72
-2.22
-1,734.65
8.45
-10.64
-86.18
-24.2
-32.21
- -
- -
- -
-0.01
-0.01
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
85
5,370
5,881
6,151
6,151
Basic Weighted Avg Shares
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Sales/Revenue/Turnover
- -
-386.97
-127.38
- -
-2,225,858.33
-178,127.56
-288,044.59
- -
- -
- -
- -
- -
-1,852.24
-1,100.86
-2,049.64
-1,440.47
-1,213.62
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
- -
-1
- -
- -
-1
-2
-21
6
-9
-3
-5
-13
-31
-13
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-393.2
-121.96
- -
-3,155,845.83
-178,692.52
-572,190.54
- -
- -
- -
- -
- -
-1,749.32
-1,082.2
-2,243.68
-5,093.56
-2,124.13
Profit Margin (%)
- -
- -
- -
- -
-1
- -
-1
1
-1
-15
-8
-16
1
-3
-3
-39
-58
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
1
1
LT Debt
- -
1
- -
- -
-1
- -
-1
1
-1
-15
-8
-16
2
-2
-4
-38
-57
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-45.71
- -
- -
- -
- -
- -
-5.33
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'24
ST Debt
11
19
23
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,151
6,151
6,151
Market Capitalization
15
6
9

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'24
Total Current Assets
- -
1
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
48
40
58
Payables & Accruals
2
4
5
ST Debt
11
19
23
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
267.64%
156.75%
902.76%
Free Cash Flow
67.63%
50.84%
7.55%
Net Income, GAAP
105.41%
7.28%
142.56%
Sales/Revenue/Turnover
- -
- -
6.85%
Total Cash Common Dividend
- -
- -
-2.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
-0.01
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Seer, Inc. (SEER)
Hansa Biopharma AB (publ) (0RC7.L)
Athira Pharma, Inc. (ATHA)
NanoLogix, Inc. (NNLX)
Arch Biopartners Inc. (ACHFF)
Biora Therapeutics, Inc. (BIOR)
Business
Theralink Technologies, Inc. (THER) operates as a commercial-stage precision medicine and molecular data-generating company focused on proteomics-based diagnostics for oncology. The company develops and commercializes patented phosphoprotein and protein biomarker platforms along with laboratory-developed tests (LDTs) that target multiple areas of oncology and drug development; its core offerings include the Theralink Reverse Phase Protein Array (RPPA) assays, which provide precision oncology data to identify likely responders and non-responders to FDA-approved and investigational treatments, laser capture microdissection for tumor sample analysis, and the Theralink Assay for Breast Cancer to support targeted treatment decisions for patients with advanced breast cancer; these services also enable biopharmaceutical companies to accelerate drug discovery, evaluate drug target inhibition, and interrogate signaling pathways in preclinical and clinical samples. Theralink Technologies serves clinical oncologists, patients, and biopharma clients across the United States, with operations centered in the biotechnology and precision medicine sectors. Founded in 2005 and headquartered at 15000 West 6th Avenue, Suite 400, Golden, Colorado 80401, the company formerly operated as OncBioMune Pharmaceuticals, Inc. prior to changing its name to Theralink Technologies, Inc. in September 2020. In recent developments, IMAC Holdings, Inc. (Nasdaq: BACK) acquired key assets from Theralink in May 2024 through a settlement agreement, enabling the continuation and commercialization of its precision medicine technologies, including breast cancer diagnostics, while transitioning personnel to stabilize operations and resolve prior debt issues stemming from a terminated 2023 merger plan.

Company News

APIChatGPT

  • globenewswire.com

    Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates

  • globenewswire.com

    Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4

  • globenewswire.com

    Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board

  • globenewswire.com

    Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023